NSAID–Gut Microbiota Interactions
- 1Department of Microbiology, University of Pennsylvania, Philadelphia, PA, United States
- 2Department of Systems Pharmacology and Translational Therapeutics, and Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, United States
Nonsteroidal anti-inflammatory drugs (NSAID)s relieve pain, inflammation, and fever by inhibiting the activity of cyclooxygenase isozymes (COX-1 and COX-2). Despite their clinical efficacy, NSAIDs can cause gastrointestinal (GI) and cardiovascular (CV) complications. Moreover, NSAID use is characterized by a remarkable individual variability in the extent of COX isozyme inhibition, therapeutic efficacy, and incidence of adverse effects. The interaction between the gut microbiota and host has emerged as a key player in modulating host physiology, gut microbiota-related disorders, and metabolism of xenobiotics. Indeed, host–gut microbiota dynamic interactions influence NSAID disposition, therapeutic efficacy, and toxicity. The gut microbiota can directly cause chemical modifications of the NSAID or can indirectly influence its absorption or metabolism by regulating host metabolic enzymes or processes, which may have consequences for drug pharmacokinetic and pharmacodynamic properties. NSAID itself can directly impact the composition and function of the gut microbiota or indirectly alter the physiological properties or functions of the host which may, in turn, precipitate in dysbiosis. Thus, the complex interconnectedness between host–gut microbiota and drug may contribute to the variability in NSAID response and ultimately influence the outcome of NSAID therapy. Herein, we review the interplay between host–gut microbiota and NSAID and its consequences for both drug efficacy and toxicity, mainly in the GI tract. In addition, we highlight progress towards microbiota-based intervention to reduce NSAID-induced enteropathy.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs worldwide for the treatment of pain, inflammation, and fever. NSAIDs exert their pharmacological effects through the inhibition of the cyclooxygenase (COX) enzyme. COX is the rate-limiting enzyme involved in the biotransformation of arachidonic acid (AA) into prostanoids, including prostaglandin (PG)E2, PGD2, PGF2α, prostacyclin (PGI2), and thromboxane (TxA2). COX exists in two isozymes, known as COX-1 and COX-2, which have different physiological functions, gene regulation, and pattern of expression (Ricciotti and FitzGerald, 2011). COX-1 is constitutively expressed in almost all tissues and is responsible for the production of prostanoids that control homeostatic functions, such as gastric epithelial cytoprotection, platelet function homeostasis, and renal blood flow regulation (Ricciotti and FitzGerald, 2011). COX-2 is an immediate response gene. Its basal expression is restricted to certain organs, including the kidney, the central nervous system, and the vasculature. COX-2 gene and protein expression are rapidly induced by inflammatory cytokines, laminar shear stress, and growth factors, and it represents the main source of prostanoid formation during the inflammatory response (Ricciotti and FitzGerald, 2011).
NSAIDs are part of a chemically heterogeneous group of compounds that can be classified on the basis of their relative inhibition of COX isozymes. Based on their selectivity for COX-1 and COX-2 inhibition achieved by therapeutic doses, NSAIDs can be broadly classified into nonselective COX inhibitors, such as aspirin, ibuprofen, indomethacin, and naproxen and selective COX-2 inhibitors, such as diclofenac and coxibs (e.g. celecoxib, rofecoxib, etc.).
Despite their efficacy in the relief of pain and inflammation, NSAIDs can cause serious adverse events such as gastrointestinal (GI) and cardiovascular (CV) complications in some individuals (Grosser et al., 2017; Bjarnason et al., 2018). The coxibs, rationally designed COX-2 selective inhibitors, were originally developed to reduce the incidence of serious GI adverse effects when compared with nonselective NSAIDs (Bjarnason et al., 2018).
GI toxicity is arguably a significant adverse effect associated with NSAID use, due to its frequency and severity. Short- and long-term use of NSAIDs can cause upper and lower GI damage, predominantly in patients with predispositions (Bjarnason et al., 2018). About 30 to 50% of NSAID users have endoscopic lesions in the GI tract. The incidence rates of upper GI toxicity (gastropathy), which is manifested with gastroduodenal ulcers, range from 5 to 80% in short-term (<1 month) endoscopy studies (Bjarnason et al., 2007) and from 15 to 40% in long-term (>3 months) users (Geis et al., 1991). The incidence rate of serious upper GI complications, which include ulcers, intestinal perforation, acute bleeding, and gut stenosis ranges between 1 and 2% in chronic (>3 months) NSAID users (Sostres et al., 2013). The signs and symptoms of NSAID-induced lower GI toxicity (enteropathy), localized distal to the ligament of Triez, are usually nonspecific, often are clinically silent, and difficult to detect. New endoscopic techniques enabled diagnosis of NSAID-induced enteropathy more easily than in the past and revealed that they may be as common and serious as upper GI complications (Shin et al., 2017). NSAID-induced toxicity in the small bowel can manifest with nausea, indigestion, constipation, diarrhea, and abdominal pain. Chronic exposure to NSAID can cause mucosal erythema, mucosal erosions and breaks, sub-epithelial hemorrhages, protein loss, anemia, strictures, and ulcerations. In the long term these lesions may become more serious but rarely cause intestinal obstruction and perforation. Small intestine permeability is present in 50–70% of long-term NSAID users, while inflammation is present in 60–70% of them (Tai and McAlindon, 2018). Lower GI mucosal damage is present in approximately 30–40% of NSAID users (Maiden et al., 2005; Sostres et al., 2013). Over the past decades, NSAID-induced peptic ulcer disease and the hospitalization rates due to upper GI complications have declined (Lanas et al., 2011; Malmi et al., 2014), paralleling the prescription of modified-release and/or enteric-coated NSAIDs, widespread use of anti-secretory drugs [e.g. proton pump inhibitors (PPIs) and histamine 2-receptor inhibitors], and reduction in Helicobacter pylori prevalence. Meanwhile, the incidence of lower GI damage associated with NSAIDs has become more perceptible (Bjarnason et al., 2018). Unfortunately, current prevention strategies that reduce the extent of damage in the upper GI tract are not effective in the lower GI tract. Potential new therapeutic strategies that aim to prevent lower GI tract damage caused by NSAIDs are reported in Table 1.
In addition to GI adverse effects, NSAIDs can cause serious CV complications. NSAIDs can raise blood pressure and cause atherothrombotic events, heart failure, arrhythmias, and sudden cardiac death (Coxib and traditional NSAID Trialists’ (CNT) Collaboration et al., 2013; Grosser et al., 2017). Randomized placebo-controlled trials have established that NSAIDs confer a CV hazard in approximately 1 to 2% of people exposed, but the absolute risk may increase with higher drug doses, frequency of use, and established CV disease (Coxib and traditional NSAID Trialists’ (CNT) Collaboration, et al., 2013; Grosser et al., 2017). The increased risk for hypertension and atherothrombotic events associated with NSAID exposure is mechanistically consistent with the inhibition COX-2 dependent formation of cardioprotective PGs (Yu et al., 2012). On other hand, NSAID may increase the risk for heart failure through a direct effect on the myocardium and vasculature remodeling and/or by altering hemodynamic stability and renal function (Patrono, 2016). The increased risk for heart failure associated with NSAID use occurs through a COX-2 dependent hazard unrelated to the degree and duration of suppression of platelet COX-1 (Coxib and traditional NSAID Trialists’ (CNT) Collaboration, et al., 2013). Thus, the risk profiles of NSAIDs can vary due to the degree to which an individual drug inhibits COX-1 or COX-2 isozymes. NSAID use is associated with interindividual variability in the extent of COX isozyme inhibition and in the occurrence of therapeutic and adverse effects (Panara et al., 1999; McAdam et al., 1999; Theken et al., 2019), which could partially be explained by pharmacokinetic variability and single-nucleotide polymorphisms (SNPs) in NSAID-metabolizing genes cytochrome (CYP) P450 isoenzymes (Karaźniewicz-Łada et al., 2009; Bae et al., 2011) and in COX genes (Fries et al., 2006; Lee et al., 2017).
The interaction between host and gut microbiota (the large community of microorganisms that resides in the gut) has emerged as a key player in modulating host physiology, gut microbiota-related disorders, and metabolism of xenobiotics (dietary components, environmental pollutants, and pharmaceuticals; Sommer and Bäckhed, 2013; Vayssier-Taussat et al., 2014; Spanogiannopoulos et al., 2016). The human gut microbiota, by modulating drug disposition, is now recognized as a novel factor driving interindividual variation in drug efficacy and side effects, including those of NSAIDs. Indeed, the heterogeneity of the gut microbiota in populations may result in different responses to drug treatment (Yip and Chan, 2015; Kashyap et al., 2017).
In this review, we discuss the field’s current knowledge of NSAID–gut microbiota interactions. We report on studies describing how NSAIDs can modify the growth and imbalance the composition of the intestinal microbial communities (condition known as dysbiosis) and the effects of these modifications on the host. In addition, we summarize research reporting the direct and indirect effects of the gut microbiota on NSAID disposition, efficacy, and toxicity, mainly related to lower GI side effects. Although we describe these interactions as separate events, in reality they are part of a dynamic and multidirectional interplay. Thus, NSAIDs may modify the composition of the intestinal microbiota and cause changes in the relative abundance of the bacterial strains involved in drug absorption and metabolism that ultimately affects NSAID therapeutic outcomes. Finally, we briefly highlight the translational implication of this research and discuss progress towards microbiota-based interventions to reduce NSAID induced lower GI side effects. In conclusion, the increasing understanding of the NSAID–gut microbiota interface could provide novel insights for the discovery and development of new anti-inflammatory drugs. Moreover, this knowledge could be used as a precision medicine-based approach to increase NSAID efficacy and prevent NSAID related toxicities.
The Gut Microbiota
The gut microbiota is a large and diverse community of microbes that inhabit the GI tract. The microbiota interacts with human cells and these interactions are very diverse due to the variability of microbial organisms in the GI tract. The different regions of the gut vary in pH, oxygen levels, epithelial cell physiology, and nutrient content; therefore, the environment in the GI tract determinates the dominant bacterial strains in the different areas and the types of metabolic processes that occur (Koppel et al., 2017).
For example, the small intestine, characterized by higher oxygen levels, has a high proportion of facultative anaerobic bacteria, including Lactobacillaceae; whereas the colon and feces, characterized by lower oxygen levels, have a high proportion of strictly anaerobic bacteria, including Bacteroidaceae, Prevotellaceae, Rikenellaceae, Lachnospiraceae, and Ruminococcaceae (Gu et al., 2013).
The gut microbiota is a highly plastic community which is influenced by numerous factors like diet, gender, environment, eating behavior, and xenobiotic and microbial metabolites. It is constituted by bacteria, archaea, viruses, fungi, and parasites, counting approximately trillions of microorganisms. The number of microbes in the intestinal tract increases from the stomach to the colon, ranging approximately from 101–104 to 1010–1012 microbes per gram of luminal content, respectively (Sender et al., 2016). Bacteria are the most abundant components of the gut microbiota. There are over a thousand bacterial species in the gut, counting approximately the same order of bacterial cells as the number of human cells. Healthy human gut microbiota is diverse and largely consists of seven phyla: Bacteroidetes, Firmicutes, Proteobacteria, Verrumicrobia, Actinobacteria, Fusobacteria, and Cyanobacteria (Sommer and Bäckhed, 2013). Although obligate anaerobes typically dominate most intestinal anatomical locations, a large range of variation in community composition is observed among individuals and among locations within the gut (Eckburg et al., 2005; Huttenhower et al., 2012). Intestinal bacteria are involved in many human physiological processes: they metabolize structurally different food molecules, including lipid and glucose metabolism, and synthesize amino acids and vitamins. In addition, they play important roles in several physiological functions like intestinal epithelial barrier, GI sensory and motor activities, mucosal immunity, systemic immune surveillance, and host behavior (Thomas et al., 2017). The microbiome is estimated to comprise ~3.3 million microbial genes (150 times more genes than the host human genome), including genes involved in xenobiotics biodegradation and metabolic pathways (Qin et al., 2010; Spanogiannopoulos et al., 2016). The gut microbiota can be considered as an important metabolic “organ” for drugs, with a metabolic capacity at least equal to that of the liver.
The gut microbiota can directly cause chemical modifications of drugs themselves or of their metabolites. The human gut microbiota is known to biotransform so far more than 50 pharmaceuticals by producing enzymes with different catalytic activities and thus determining the bioactivity, bioavailability, and toxicity of several natural or synthetic substances (Koppel et al., 2017; Wilson and Nicholson, 2017; Collins and Patterson, 2020). Drugs taken orally can encounter gut microbes mainly in the small or large intestine or through biliary excretion.
The reactions catalyzed by bacterial enzymes include: reduction, hydrolysis, hydroxylation, dihydroxylation, dealkylation, deamination, decarboxylation, acetylation, deacetylation, and rarely oxidation (Sousa et al., 2008; Wilson and Nicholson, 2017). The major bacterial enzyme families involved in drug metabolism are: β-glucuronidases, azoreductases, demethylases, desulfatases, sulfoxide reductase, and cardiac glycoside reductases (Wilkinson et al., 2018; Collins and Pattersons, 2020). In contrast, the host enzymes, CYP P450 and phase II drug metabolizing enzymes, participate in drug metabolism mainly by oxidation or conjugation reactions (Sousa et al., 2008). Gut microbial metabolism of drugs generates metabolites with active, inactive, or toxic properties (Li et al., 2016). The formation of these microbial metabolites occurs concurrently and often competing with host metabolic processes. Thus, the chemistry of microbial transformations is distinct from that of host enzymes, and it can oppose or reverse host metabolism, ultimately altering the pharmacokinetics and pharmacodynamics of xenobiotics and their metabolites. In addition, whereas host metabolism occurs to detoxify the body from xenobiotics, microbial modifications occur generally to provide nutrients and energy to the microbes.
The synergism between the host and the microbiota generates metabolites that would not be synthesized by the host alone and can alter the biological activities and duration of xenobiotics. For example, the NSAID sulindac is a pro-drug that requires gut bacteria to be converted in the active compound sulindac sulfide (Strong et al., 1987). Additionally, bacterial metabolites can compete with drugs for host metabolic enzymes. For example, the production of p-cresol by bacteria competes with the human cytosolic sulfotransferase involved in the metabolism of acetaminophen, so that increase production of p-cresol causes decreased acetaminophen O-sulfonation and increased glucuronidation (Clayton et al., 2009). Another example is represented by the Parkinson’s disease medication Levodopa (L-dopa), which is metabolized first by a pyridoxal phosphate-dependent tyrosine decarboxylase from Enterococcus faecalis, followed by a molybdenum-dependent dehydroxylase from Eggerthella lenta. L-dopa degradation in human stool samples can be predicted predominantly by tyrosine decarboxylase gene expression and abundance of Enterococcus faecalis and Eggerthella lenta (Maini Rekdal et al., 2019). Moreover, bacterial enzymes, like β-glucuronidase, β-glucosidase, demethylase, desulfatases, and other phase II reversing enzymes, can remove small molecules attached to the drug by host enzymes during the drug metabolism. This process makes the free parent drug molecule available for reabsorption (enterohepatic circulation) by the host and thus increases the exposure of the host to the drug itself or its metabolites. This kind of reabsorption prolongs the exposure of drugs in the body (higher half-life) and often contributes to toxicity (Boelsterli et al., 2013).
In addition, the gut microbiota can indirectly influence the drug fate. The gut microbiota can limit drug absorption in the small intestine by increasing the expression of cell–cell adhesion proteins, thickening the protective mucosal layer, and/or directly sequestering chemicals to prevent their absorption (Collins and Pattersons, 2020). These processes can influence the bioavailability of the drugs with consequences for drug toxicity (at the body site where the drug is bioaccumulated) and/or drug effectiveness (since lower concentrations of drugs are circulating). Furthermore, the gut microbiota can regulate host expression of genes involved in vary metabolic pathways, including nuclear receptor regulation, phase I and II enzymes, and transporters (Collins and Pattersons, 2020). Moreover, the gut microbiota can produce microbial metabolites that can compete with drug metabolism (Sun et al., 2019).
Thus, microbes that reside in the human gut are considered a newly recognized modulator of drug exposure and consequently of variability in drug response, but they may also represent a potential source of new therapeutics.
Impact of Nsaids on Gut Microbiota Composition and Metabolic Activity
Medication has recently emerged as one of the most influential determinants of the gut microbiota composition and activity (Falony et al., 2016; Zhernakova et al., 2016; Maier et al., 2018). Several classes of drugs can shape the physiome of the gut microbiota by shifting the composition of the intestinal microbial communities (Maurice et al., 2013; Mani et al., 2014). Some drugs determine a shift of the microbiota composition to favor the abundance of microbial taxa involved in its metabolism. This shift could consequently affect the pharmacokinetic proprieties of subsequent doses of the drug itself and the pharmacokinetics of co-administered medications (Walsh et al., 2018).
NSAID use can affect the gut microbiota composition and metabolic activity through a direct effect on the microbiota (e.g. by inhibiting/facilitating microbial growth, inducing microbial cell death and/or influencing microbial metabolism) or through an indirect effect by interacting with the host (e.g. by changing the metabolism, gut environment, mucosa integrity, and permeability, Figure 1). Both selective and nonselective NSAIDs can affect the composition of the gut microbiota in animals and in humans (Table 2).
Figure 1 Dynamic interactions between NSAID and gut microbiota. NSAID Direct effects: NSAIDs can have antibacterial properties that directly affect the composition of the gut microbiota (by effecting bacterial metabolism/growth, and/or inducing microbial cell death). NSAID Indirect effect: NSAIDs can alter the physiological properties or functions of host organs (e.g. by changing the gut environment, changing mucosa integrity and permeability, and interfering with host and microbial metabolism) which may, in turn, precipitate in dysbiosis. Gut Microbiota Direct effects: the gut microbiota can directly biotransform orally and systemically administrated drugs into other chemical forms or metabolites, which may have altered efficacy or toxicity. Gut Microbiota Indirect effects: the gut microbiota can indirectly impact the efficacy and toxicity of drugs by altering the host metabolism capacity or processes (by influencing hepatic function, altering expression of hepatic enzymes or metabolic genes, interfering with detox pathway).
Several animal studies have shown that NSAID administration causes significant changes in the intestinal microbiota, often increasing the abundance of Gram-negative bacteria (Kent et al., 1969; Honda et al., 1999; Otani et al., 2017; Vázquez-Baeza et al., 2018). Subcutaneous treatment with indomethacin increases intestinal Enterococcus faecalis and decreases segmented filamentous bacteria in the small intestine and mesenteric lymph nodes in female rats (Dalby et al., 2006). Similarly, systemic administration of indomethacin causes intestinal inflammation, characterized by upregulation of Toll-like receptor (TLR)-2 and -4 in the intestine and increases the abundance of Bacteroides and Enterobacteriaceae in the ileum and cecum-colon and Clostridium the in ileum of male rats (Terán-Ventura et al., 2014). In mice, a single oral administration of indomethacin causes lesions in the small intestine, increases the richness of the microbiota in the large intestinal content and feces, with an expansion of pro-inflammatory bacteria, reduces the diversity of the microbial species in the cecum and large intestinal mucosal content, and increases the microbial diversity in the feces. Meanwhile, one-week treatment with a diet containing indomethacin decreases the diversity of the microbiota only in the cecum luminal content, probably indicating a recovery of the gut microbiota during chronic drug exposure (Liang et al., 2015). In contrast, another study reports that a single oral administration of indomethacin does not cause small intestinal damage but induces adaptive beneficial changes in the gut microbiota, including increased abundance of Firmicutes and decreased abundance of Bacteroidetes, which may be protective against indomethacin-induced enteropathy in mice (Xiao et al., 2017). In fact, the administration of antibiotics after indomethacin treatment increases the mortality due to GI lesions, while naïve mice transplanted with adaptively changed microbiota collected from mice previously treated with indomethacin, show smaller intestinal damage in response to indomethacin.
Diet and dietary additives can increase the vulnerability to indomethacin induced-enteropathy. High fat diet aggravates indomethacin-induced small intestinal damage in mice via intestinal dysbiosis, increases gene expression of interleukin (IL)-17A in the intestine and augments intestinal permeability (Sugimura et al., 2019). A dietary emulsifier, polysorbate 80, exacerbates indomethacin-induced small-intestinal lesions via intestinal dysbiosis and increases protein expression of IL-1β in the small intestine (Furuhashi et al., 2019). A possible mechanism by which indomethacin can cause the translocation of luminal bacteria from the lumen into the mucosa is by altering the content of sugars and lipids in the glycocalyx layer of the mucosa (Basivireddy et al., 2005). Indomethacin-induced dysbiosis has also been associated with intestinal infections. Indomethacin increases the severity of Clostridium difficile infection (CDI) by perturbing the gut microbiota and dysregulating intestinal inflammatory response in a mouse model of antibiotic-associated CDI (Maseda et al., 2019). Similarly, both low and high doses of indomethacin increase the severity of Clostridium difficile infection in two different mouse models of antibiotic-associated CDI (Muñoz-Miralles et al., 2018). Such findings support epidemiological data linking NSAID exposure and CDI and warn against the use of NSAIDs in patients at high risk for Clostridium difficile (Permpalung et al., 2016).
Short oral treatment with naproxen causes intestinal ulceration and inflammation, increases bile cytotoxicity, and shifts the jejunal microbiota composition in rats (Syer et al., 2015). Naproxen decreases the abundance of Lachnospiraceae family (from the Gram-positive Clostridia class) and increases the Bacteroides genus (from the Gram-negative Bacteroidia class) in the rat jejunum (Syer et al., 2015). Similarly, short term oral administration of diclofenac increases intestinal permeability and ulceration and augments the number of Gram-negative bacteria in rat ileum (Reuter et al., 1997). In a recent study, intragastrical treatment with diclofenac for 14 days caused small intestinal damage and inflammation characterized by an increased protein expression of TLR-2 and TLR-4 and biosynthesis of IL-1β and tumor necrosis factor-α (TNF-α) (Colucci et al., 2018) in the ileum. Moreover, diclofenac-induced enteropathy is associated with an increase in the relative abundance of Proteobacteria and Bacteroidetes and a decrease in Firmicutes in the rat ileum.
Chronic oral treatment with celecoxib also alters the intestinal microbiota, causing an increase in Coriobacteriaceae and decrease in Bifidobacteriaceae and Lactobacillaceae abundance in both ileal content and feces, and this effect is associated with the reduction of polyp burden in APC Min/+ mice. Moreover, celecoxib alters the fecal metabolite profile and diminishes the content of amino acids, dipeptides, lipids, nucleotides and glucose (Montrose et al., 2016). In contrast, a long-term intragastrical treatment with rofecoxib does not cause small intestinal damage and does not influence the composition, richness, and diversity of the jejunal microbiota in rats (Lázár et al., 2019). The result of this study may indicate that, in addition to COX-2 inhibition, the microbial alterations caused by some NSAIDs may be due to drug-specific properties that determine topical epithelial damage.
There is also some initial evidence that NSAIDs can alter the oral microbial composition. Two-weeks of intragastrical treatment with aspirin increases oral microbial diversity and content in rats (Cheng et al., 2018). In particular, the Lactobacillaceae abundance is increased significantly by aspirin. Furthermore, aspirin reduces the immunoglobulin (Ig)G and secretory IgA content in the saliva. On the contrary, a short oral treatment with aspirin does not have an impact on the Gram-negative bacterial counts in the ileum and does not cause small intestinal damage in rats (Reuter et al., 1997).
Although the overgrowth of specific bacteria after NSAID administration has been recognized for several decades, the reasons for NSAID-induced dysbiosis are not known. One hypothesis is that certain NSAIDs could have antibacterial activity as reported in vitro for indomethacin, diclofenac, ibuprofen, aspirin and celecoxib (Annadurai et al., 2002; Shirin et al., 2006; Obad et al., 2015; Thangamani et al., 2015; Chan et al., 2017; Maier et al., 2018). In mouse infection models, diclofenac has shown to be effective against Salmonella Typhimurium (Dastidar et al., 2000; Annadurai et al., 2002), and celecoxib has shown to be efficacious in a methicillin-resistant S. aureus skin infection (Thangamani et al., 2015). However, it still remains unknown whether the antibacterial activity of NSAIDs occurs with therapeutic concentrations of the drugs in vivo; it could be responsible for the dysbiosis observed with NSAIDs, and it could be implicated in NSAID-induced enteropathy.
The impact of NSAID administration on the human intestinal microbiota has been less explored due to the difficulties associated with this type of investigations. NSAID users can present different gut microbiota profiles from that of nonusers, as do users of specific types of NSAIDs (Rogers and Aronoff, 2016). For example, treatment with aspirin causes a shift in the composition of the gut microbiota regarding Prevotella, Bacteroides, Ruminococcaceae, and Barnesiella, whereas celecoxib and ibuprofen increase the abundance of Acidaminococcaceae and Enterobacteriaceae. Ibuprofen causes enrichment in Propionibacteriaceae, Pseudomonadaceae, Puniceicoccaceae, and Rikenellaceae species compared with either nonusers or naproxen users.
The composition of the gut microbiota of NSAID and PPI users differs from that of only NSAID users in the abundance of Bacteroides and Erysipelotrichaceae species. Furthermore, Bacteroides species and a bacterium of family Ruminococcaceae differ between NSAID users and antidepressant and laxative users (Rogers and Aronoff, 2016). Thus, these data indicate that the profile of bacteria in the GI tract reflects the combinations of medicines ingested. This is in agreement with the fact that the co-administration of drugs may cause changes in the composition of the microbiota to favor the abundance of taxa that have metabolizing capacity for those drugs (Ticinesi et al., 2017). In contrast to the aforementioned study, celecoxib does not alter the composition of the gut microbiota in a longitudinal study in post-menopausal obese women (Bokulich et al., 2016). In this small study, the inter-individual variability in response to celecoxib could have masked the effect of this drug on the diversity of the gut microbiota. On this note, a recent study reported that without altering the composition of the microbiota, celecoxib can decrease microbial butyrate production in a human intestinal microbiota ecosystem model and also diminish markers of inflammation like IL-8 and CXCL16 in intestinal cells in vitro (Hernandez-Sanabria et al., 2020).
Although these are the first studies investigating a possible shift in the composition of the gut microbiota by NSAIDs in humans, some of these studies did not take into account confounding factors (e.g. primary disease conditions, concomitant use of other medications, drug dose, drug exposure, time of drug intake, sex, diet, and age) and lacked appropriate controls. Indeed, both age and sex can influence the impact of NSAIDs on the composition of human gut microbiota. In terms of age-related differences, the total number of microbes is reduced in older (between 70 and 85-year-old) compared with younger subjects (mean age 28 years), but it is higher in the senior NSAID users compared with senior nonusers. However, the fecal microbiota composition of older subjects using NSAIDs presents a reduction of the abundance in Collinsella, Actinobacteria, and Lactobacilli, compared to older nonusers and young adults (Mäkivuokko et al., 2010).
In terms of sex-related differences, women present lower intestinal permeability and higher microbial diversity than man (Edogawa et al., 2018). Intestinal permeability is sensitive to perturbation following acute treatment with indomethacin, but returns to baseline 4–6 weeks after discontinuation of the drug in both sexes. Fecal and duodenal gut microbiota diversity decreases after acute treatment with indomethacin, especially in women, which recovers 4–6 weeks later. Women present greater abundance of Actinobacteria phylum but lower abundance of Bacteroidetes and Proteobacteria compared to men (Edogawa et al., 2018).
In addition to the demographic factors, psychological stress can exacerbate indomethacin-induced small bowel injury in mice by increasing the total number of bacteria and the proportion of gram-negative bacteria and by increasing the permeability of intestinal mucosa via glucocorticoid receptor signaling (Yoshikawa et al., 2017). This study indicates that the microbiota–gut–brain axis may play an important role in the development of NSAID-induced enteropathy as reported also for other pathological conditions (Collins and Bercik, 2009).
Future studies should be designed to include larger and more diverse cohorts and be carried longitudinally. Moreover, more work and complex analysis (e.g., multi-omics and longitudinal studies) are needed to go beyond associations and determine causality.
Impact of the Gut Microbiota on Nsaid Disposition, Toxicity and Efficacy
The gut microbiota can have direct and indirect effects on drug absorption, distribution, metabolism and excretion, and consequently affect drug efficacy and toxicity (Wilson and Nicholson, 2017). In the case of the NSAIDs, the gut microbiota can directly biotransform orally and systemically administrated drugs into other chemical forms or metabolites, which may have altered efficacy or toxicity (Figure 1). Different microbial, fungal, and yeast cultures are capable of biotransforming valdecoxib and celecoxib in vitro (Keshetti and Ciddi, 2010; Srisailam and Veeresham, 2010). Moreover, flurbiprofen is converted by the zygomycete fungus Cunninghamella to a variety of metabolites in different mammals, including humans (Amadio et al., 2010). Furthermore, the gut microbiota can indirectly impact the efficacy and toxicity of drugs by altering the host metabolism capacity (by influencing hepatic function, altering expression of hepatic enzymes or metabolic genes, interfering with detox pathway) (Figure 1).
While few studies show the influence of the gut microbiota on NSAID metabolism and efficacy, several reports indicate its involvement in NSAID-induced lower GI toxicity. Compositional changes of the gut microbiota associated with indomethacin administration can alter both its disposition and consequently its inhibitory effect on prostanoid biosynthesis via de-glucuronidation of its metabolites during enterohepatic recirculation. Antibiotic suppression of intestinal bacteria significantly reduces the level of indomethacin de-glucuronidation, resulting in increased elimination, a shortened half-life, and reduced drug exposure (Liang et al., 2015).
Reduction of metabolic activity of the gut microbiota by oral antibiotics reduces the host metabolism of orally administrated aspirin and increases its antithrombotic effects in rats. However, aspirin metabolism is not changed by antibiotics administrated intravenously (Kim et al., 2016). This study represents the first evidence of the impact of the gut microbiota on the NSAID effects on the CV system. Similarly, the oral administration of amoxicillin reduces the pharmacokinetics of aspirin by slowing down the metabolic activity of the gut microbiota involved in the biotransformation of aspirin in rats (Zhang et al., 2019). These findings indicate that antibiotics could interfere with the gut microbiota metabolism of some NSAIDs, frequently prescribed together in the clinical setting, and affect their bioavailability and efficacy.
The mechanisms underlying NSAID-induced enteropathy are still not completely understood. Our current knowledge indicates that the pathogenesis of NSAID-induced small intestinal damage is a multifactorial process that occurs in response to multiple insults (Davies et al., 2000; Boelsterli et al., 2013). NSAIDs can cause intestinal damage through topical irritant effects due to the direct contact of the drug with the intestinal mucosa, local inhibition of protective PGs, and interaction with the gut microbiota.
The topical effects are caused by physiochemical proprieties of the drugs. These are COX-independent effects linked to the drug acidity and/or lipophilicity (most NSAIDs are lipid-soluble weak organic acids). The topical effects caused by NSAIDs are relevant to oral drug administration but also to parental administration due to hepatobiliary excretion of active metabolites and their enterohepatic cycling (Boelsterli et al., 2013). On the contrary, the local inhibition of protective PGs is a COX-dependent effect related to the drug potency and selectivity for the inhibition of COX isozymes. Indeed, there are differences between individual NSAIDs and their risk of inducing small intestinal damage in humans (Sigthorsson et al., 1998; Davies et al., 2000).
Drugs present in the intestinal lumen initially interact with the intestinal mucus layer and the cell surface phospholipid bilayer, where they can trigger drug-induced mithocondrial and endoplasmic reticulum damage, and oxidative stress in epithelial cells, all detrimental events that coalesce to impair healthy GI function. These topical effects strongly increase the permeability of the intestinal mucosa and lead to a low-grade inflammation, which facilitates the entrance and action of luminal aggressors (bile, intestinal enzymes, and commensal bacteria) in the small bowel (Bjarnason et al., 2018). The concurrent COX inhibition and the presence of luminal aggressors increase the severity of inflammatory and ulcerative damage causing mucosal erosions and ulcers (Bjarnason et al., 1993; Somasundaram et al., 1997; Wallace, 2012). Indeed, NSAID administration can increase intestinal permeability within 12–24 h after drug intake, mainly in the jejunum and ileum, and cause inflammation in the small intestine within 10 days, while ulcer formation can take up to 2 weeks (Bjarnason et al., 2018).
There are controversial pieces of evidence regarding which COX isozymes are expressed in the intestine and the degree of their involvement in the development of lower GI toxicity. In the small intestine, PGs are implicated in the maintenance of blood flow, turnover of epithelial cells, mucus secretion, intestinal motility, mucosal repair, and inflammatory response. Intestinal PGs are produced mainly by COX-1 since COX-2 seems to have little or no gene/protein expression in the healthy intestine (Kargman et al., 1996; Takeuchi et al., 2010a; Bjarnason et al., 2018). However, some reports indicate constitutive expression of COX-2 gene/protein in the intestine of some animal species (Haworth et al., 2005; Fornai et al., 2014; Kirkby et al., 2016). Additional studies indicate that COX-1 is mainly responsible for the production of endogenous PGs involved in mucosal protection, with COX-2 contributing to mucosal defense only under conditions or inflammation, while, while both COX-1 and COX-2 are involved in the healing of small intestinal lesions (Takeuchi and Amagase, 2018).
Genetic and pharmacological studies in animal models have helped to understand the pathophysiological functions of COX-1 and COX-2 and of their products in the GI tract. Cox-1 deficient mice do not exhibit spontaneous gastric ulcers despite low mucosal PG levels (Langenbach et al., 1995; Loftin et al., 2002). The gastric pH is lower in Cox-1 deficient mice than in wild-type and Cox-2 deficient mice (Langenbach et al., 1999), consistent with the Cox-1 dependent secretion of acid and/or bicarbonate in the stomach. Thus, although the suppression of COX-1-derived PGs increases stomach acidity, this is not sufficient to induce gastric lesions. Traditional Cox-2 deficient mice, which have a reduced life-span due cardio-renal defects, present normal PG level and no gastric ulcers (Morham et al., 1995; Loftin et al., 2002). Similarly, rodents treated with the COX-1 inhibitor SC-560 or with selective COX-2 inhibitors do not present upper GI lesions (Futaki et al., 1993; Masferrer et al., 1994; Wallace et al., 2000; Gretzer et al., 2001; Tanaka et al., 2001). Indeed, dual inhibition of both COX-1 and COX-2 is needed to cause damage in the upper GI tract as observed with nonselective NSAIDs and with COX-1 or COX-2 inhibitors in rodents (Langenbach et al., 1995; Wallace et al., 2000; Tanaka et al., 2001).
Similarly, in the small intestine, Cox-1 deficiency or inhibition with SC-560 does not cause ulcers in mice despite a significant reduction in intestinal PGE2 levels (Sigthorsson et al., 2002), while Cox-2 deficient mice present peritonitis with intestinal inflammation and fibrosis (Morham et al., 1995). Short term COX-2 inhibition with celecoxib or rofecoxib does not reduce intestinal mucosal PGE2 and does not cause intestinal damage (Sigthorsson et al., 2002; Tanaka et al., 2002a; Ohno et al., 2004; Hotz-Behofsits et al., 2010), while long-term Cox-2 deficiency or inhibition leads to disruption of the small bowel barrier function, intestinal chronic inflammation, and microscopically ileal ulcers in male and female mice despite normal PGE2 levels (Sigthorsson et al., 2002). However, the lesions caused by long-term COX-2 suppression have a different localization (terminal ileum vs mid to small intestine) and histopathologic appearance compared to the ones caused by acute exposure to nonselective NSAIDs (Sigthorsson et al., 2002). In contrast, long-term COX-2 inhibition with rofecoxib does not reduce intestinal mucosal PGE2 content, does not cause mucosal damage, and does not alter the composition of the intestinal microbiota in male rats (Lázár et al., 2019). The results of these studies indicate that other factors (i.e. sex, age, diet, environment, drug metabolism, physicochemical properties of the drug), in addition to COX-2 inhibition, maybe be contributing to the formation of the intestinal damage observed with long term exposure to celecoxib.
Dual inhibition of COX isozymes (with nonacidic compounds like SC-560 and rofecoxib or celecoxib) causes lower GI damage as well the use of COX-1 or COX-2 inhibitors in Cox-2 or Cox-1 deficient mice (Sigthorsson et al., 2002; Tanaka et al., 2002a; Hotz-Behofsits et al., 2010; Takeuchi et al., 2010a; Takeuchi and Satoh, 2015). Similarly, NSAIDs that inhibit both COXs, such as indomethacin, diclofenac, naproxen, and flurbiprofen, severely damage the small intestine in rodents (Reuter et al., 1997; Konaka et al., 1999; Tanaka et al., 2002a; Syer et al., 2015; Takeuchi and Satoh, 2015; Colucci, et al., 2018).
These studies indicate that inhibition of both COX isozymes is required for the development of intestinal lesions after short NSAID exposure, with or without the presence of an NSAID that causes topical effects (Sigthorsson et al., 2002; Hotz-Behofsits et al., 2010). Intestinal damage can also result as a consequence of COX-2 deletion or inhibition and the presence of an NSAID with topical effects as shown in Cox-2 deficient mice treated with (R)-2-phenyl propionic acid, a compound that causes topical irritant effects but does not have COX inhibitory activity, and in wild-type mice treated with celecoxib and (R)-2-phenyl propionic acid (Hotz-Behofsits et al., 2010). COX-1 inhibition alone is not sufficient to cause lower GI damage probably because COX-1 inhibition triggers compensatory mechanisms to overcome the functional consequences of PG deficiency like upregulation of COX-2 or inducible nitric oxide gene/protein expression in the intestinal mucosa (Tanaka et al., 2002a; Tanaka et al., 2002b; Takeuchi et al., 2010a; Takeuchi and Satoh, 2015). Moreover, these studies indicate that suppression of prostaglandin synthesis by NSAIDs seems unlikely to be a major contributor to the development of NSAID-induced small intestinal injuries compared to other factors since both Cox-1 deficient mice and wild-type mice treated with SC-560 do not present intestinal damage, although they present a significant reduction of intestinal PGE2 (Melarange et al., 1992; Reuter et al., 1997; Sigthorsson et al., 2002).
Many of the results obtained in animal studies were confirmed by clinical trials with coxibs. These drugs present equal clinical efficacy compared to nonselective NSAIDs and improved gastric tolerability, as assessed by short-term (Lanza et al., 1999) or long-term (Simon et al., 1999; Hawkey et al., 2000) endoscopic studies and by GI outcomes studies (Bombardier et al., 2000; Silverstein et al., 2000). On the contrary, long exposures with coxibs and nonselective NSAIDs cause similar prevalence of small bowel damage, indicating a role for COX-2 in maintaining the mucosal integrity in the small intestine (Maiden et al., 2007; Maiden, 2009). However, selective COX-2 inhibitors may cause less severe mucosal lesions than nonselective NSAIDs (Maehata et al., 2012).
Although Cox-1 or Cox-2 deficient mice do not present spontaneous intestinal ulcers, Cox-1 deficient mice and mice treated with a COX-1 or a COX-2 inhibitor retarded healing of pre-existing ulcers (Blikslager et al., 2002; Hatazawa et al., 2006). It is noteworthy to mention that of the healing process, PGE2 is produced mainly by COX-2, while in the late phase PGE2 is produced mainly by COX-1 activity (Hatazawa et al., 2006; Takeuchi and Amagase, 2018).
The effect of PGE2 in mediating the healing of small bowel lesions occurs mainly through PGE2 receptor 4 (EP4), and this effect is functionally associated with stimulation of angiogenesis via the up-regulation of vascular endothelial growth factor expression (Takeuchi et al., 2010b; Takeuchi, 2014). Indeed, supplementation with PGE2 analogs prevents NSAID-induced enteropathy and promotes the healing of intestinal ulcers in animal models (Kunikata et al., 2001; Kunikata et al., 2002; Hatazawa et al., 2006), however, the FDA-approved oral PGE1 analogue misoprostol showed mixed results in clinical studies (Bjarnason et al., 1989; Davies et al., 1993; Watanabe et al., 2008b; Fujimori et al., 2009; Kyaw et al., 2018; Taha et al., 2018). In addition, misoprostol has often shown unfavorable side effects such as diarrhea, abdominal pain, or bloating, and therefore, it is not generally suitable for its long-term use (Handa et al., 2014).
The abundance and the diversity of bacteria present in the small intestine play an important role in the pathogenesis of NSAID-induced enteropathy. NSAID use can modify the composition of the gut microbiota and induce mainly the overgrowth of Gram-negative and anaerobic bacterial species, which, possibly through release of endotoxin or microbial metabolites, lower mucosal defense and increase the susceptibility to intestinal damage (Hagiwara et al., 2004; Lanas and Scarpignato, 2006; Scarpignato, 2008; Syer et al., 2015). Germ-free rodents develop little or no intestinal lesions after NSAID exposure, but when colonized by specific Gram-negative or Gram-positive bacteria, these animals become sensitive to NSAID-induced small intestinal damage. For example, germ-free rats are resistant to indomethacin-induced enteropathy, in contrast germ-free rats colonized with Escherichia coli develop severe lesions in the gut (Robert and Asano, 1977). Moreover, a COX inhibitor, 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl) thiophene (BFMeT), is unable to induce ulcers in germ-free rats and in gnotobiotic rats mono-associated with Lactobacillus acidophilus or Bifidobacterium adolescentis; whereas BFMeT induces ileal ulcers in gnotobiotic rats colonized with Eubacterium limosum or Escherichia coli (Uejima et al., 1996). Several studies (Table 3) have reported that the treatment with large spectrum antibiotics can reduce the severity of NSAID-induced intestinal damage in animal models (Kent et al., 1969; Uejima et al., 1996; Koga et al., 1999; Leite et al., 2001) and in humans (Bjarnason et al., 1992; Scarpignato et al., 2017). For example, indomethacin-induced intestinal damage is partially prevented by the pre-treatment with poorly absorbed antibiotics in rats (Konaka et al., 1999; Fornai et al., 2016). Also, naproxen causes a significant shift in the microbiota composition of rats, and treatment with a cocktail of antibiotics reduces the severity of naproxen-induced small intestinal ulceration (Syer et al., 2015). Diclofenac-induced enteropathy is reduced by rifaximin, a broad-spectrum oral antibiotic, through both anti-bacterial and anti-inflammatory activities in rats (Colucci et al., 2018). In addition, some studies propose that antibiotic treatment may also facilitate the healing of intestinal lesions (Kent et al., 1969; Zwolinska-Wcislo et al., 2011). In addition, metronidazole, an antimicrobial targeting most Gram-negative and Gram-positive anaerobic bacteria, reduces the occurrence of NSAID-induced enteropathy in rats and in humans (Bjarnason et al., 1992; Yamada et al., 1993). However, the fact that antibiotics cannot completely prevent the NSAID-induced ulceration indicates that additional factors are involved in causing the initial intestinal damage.
Table 3 In vivo studies reporting the impact of antibiotic treatment on NSAID disposition, toxicity and efficacy.
The use of other drugs co-prescribed with NSAIDs, like for example PPIs, can have deleterious effects on small-bowel lesions, possibly through a combination of intestinal dysbiosis and increased intestinal permeability. In rats, PPIs significantly exacerbate naproxen- and celecoxib-induced intestinal ulceration and bleeding by causing a reduction of the jejunal content of Actinobacteria and Bifidobacteria, probably through changes of the pH in the GI tract over an extended period of time (Wallace et al., 2011). In germ free mice, the colonization with Bifidobacteria-enriched intestinal flora prevents the NSAID and PPI-induced small intestinal damage, whereas the colonization with bacteria from PPI-treated rats facilitates the development of NSAID-induced enteropathy (Wallace et al., 2011). Similarly, a recent study reports that PPIs aggravates indomethacin induced-enteropathy by reducing the population of Lactobacillus Johnsonii in the small intestine of mice (Nadatani et al., 2019). Consistent with the results of these animal studies, human data revealed that PPI use represents a risk factor for NSAID-induced small intestinal damage (Watanabe et al., 2013; Endo et al., 2014; Lué and Lanas, 2016; Washio et al., 2016). In addition, a meta-analysis of clinical studies comparing small intestinal bacterial overgrowth (SIBO) risk among adult users of PPIs vs nonusers indicates that the use of PPIs is associated with SIBO, a condition that can cause excessive fermentation and inflammation, leading to a variety of clinical complaints including bloating and diarrhea (Lo and Chan, 2013). Thus, dysbiosis secondary to PPI use may exacerbate the NSAID-enteropathy.
The involvement of Gram-negative bacteria in the pathogenesis of NSAID-induced enteropathy seems to be linked to the activation of toll like receptor (TLR)4 that enhances inflammation and contributes to intestinal lesions (Watanabe et al., 2008a; Nadatani et al., 2012; Higashimori et al., 2016). Increased intestinal permeability, migration of bacteria through the epithelium into the deeper layers of the mucosa, and mucosal inflammatory and immune response can be observed when the mucosal barrier function is disrupted by NSAID-mediated topical effects and prostanoid inhibition. Lipopolysaccharide (LPS) and high mobility group box 1 (HMGB1), when present in the lumen, can activate NLRP3 inflammasome through the binding to TLR4 in the intestinal cells, causing infiltration of neutrophils and macrophages and resulting in deep ulceration of the small intestinal mucosa. The activation of macrophages causes the release of pro-inflammatory cytokines such as TNF-α, IL-1β, neutrophil recruiting chemokines, and nitric oxide, which then induce neutrophil infiltration into the intestinal mucosa and submucosa. Neutrophil activation damages the small intestine through the release of cytotoxic agents like reactive oxygen species, elastases, and proteases (Bertrand et al., 1998; Konaka et al., 1999; Whittle, 2003; Hagiwara et al., 2004; Watanabe et al., 2008a; Nadatani et al., 2012; Whitfield-Cargile et al., 2016). A recent study also indicates a role for Gram-positive microorganisms in the pathogenesis of NSAID-induced enteropathy since increased protein expression of both TLR2 (which binds the outer membrane of Gram-positive bacteria) and TLR4 (which binds major cell wall components of Gram-negative bacteria) and an increased biosynthesis of IL-1β have been reported in a rat model of diclofenac-induced small intestinal damage (Colucci et al., 2018).
Neutrophils are important effector cells involved in NSAID-induced small intestinal damage since depletion of neutrophils from mice or rats reduced intestinal lesion formation in response to NSAIDs (Chmaisse et al., 1994; Watanabe et al., 2008a). On the other hand, macrophages that reside in the small intestine regulate the integrity of the epithelial barrier via secretion of IL-10 (Morhardt et al., 2019). This anti-inflammatory cytokine plays a critical role in intestinal homeostasis and in the restoration of the epithelial barrier after NSAID-driven damage, in a process that does not seem to be directly regulated by T and B cells or the gut microbiota (Morhardt et al., 2019). T cells seem dispensable to trigger NSAID-induced enteropathy since both euthymic and athymic nude rats develop intestinal ulcers following administration of indomethacin to the same degree than conventional rats (Koga et al., 1999). However, deficiency in specific T-cell subsets like, γδ T-cells in intestinal intraepithelial lymphocytes (IEL), leads to an increased sensitivity to NSAID-induced small intestinal damage in mice (Sumida et al., 2017). Additionally, GPR55-deficiency or antagonism protects mice from indomethacin-induced intestinal leakage since GPR55 acts as a negative regulator of γδ T-cell IEL accumulation and homing to the small intestine, and it also antagonizes indomethacin-induced γδ T-cell egress from Peyer’s patches (Sumida et al., 2017). Moreover, Peyer’s patches play protective roles in indomethacin-induced enteropathy through the induction of immune-regulatory CD103+ dendritic cells and IL-10-expressing CD4+ T cells in the gut-associated lymphoid tissue (Hiyama et al., 2014).
Most NSAIDs, including derivatives of enolic acid (piroxicam), propionic acid, (such as ketoprofen, naproxen, ibuprofen and flurbiprofen), and acetic acid (such as diclofenac and indomethacin), are detoxified by addition of glucuronic acid moieties by UDP-glucuronosyltransferase (UGT) in the liver and excreted in the bile via the conjugate export pump multidrug resistance-associated protein 2 (Mrp2; Treinen-Moslen and Kanz, 2006). In the gut, the glucuronic acids are enzymatically cleaved from drug conjugates by microbial β-glucuronidase, encoded by the inducible gus gene (Little et al., 2018). All major bacterial phyla present in the mammalian GI tract (Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, Clostridium, and Bifidobacterium) express the gus gene (Pollet et al., 2017; Currò, 2018). However, β-glucuronidase activity varies depending on the bacterial species and the anatomical location along the small intestine (Mani et al., 2014). The reactivation of previously detoxified NSAIDs conjugates via enterohepatic circulation plays an important role in the pathogenesis of NSAID-induced enteropathy. Enterohepatic recirculation of NSAID determines repeated and prolonged exposures of the intestinal mucosa to relatively higher concentrations of the active molecules (Reuter et al., 1997; Seitz and Boelsterli, 1998; Boelsterli et al., 2013; Liang et al., 2015; Zhong et al., 2016).
Studies with β-glucuronidase inhibitors further support the hypothesis that enterohepatic circulation is an important factor in the development of NSAID-induced enteropathy. A small molecule inhibitor of bacterial β-glucuronidase, Inh1, can reduce the number and size of intestinal ulcers in mice treated systematically with diclofenac, without modifying the pharmacokinetics of diclofenac (LoGiudice et al., 2012). Similarly, Inh1 alleviates ketoprofen-or indomethacin-induced enteropathy in mice, without interfering with the biliary excretion of NSAID conjugates (Saitta et al., 2014). Inh1 is specific for β-D-glucuronidase and it does not affect mammalian orthologue β−glucuronidases (which are essential for proper lysosomal storage) and does not kill bacteria or mammalian cells (Wallace B. D. et al., 2010), indicating that the bacterial form is the major target (LoGiudice et al., 2012). Moreover, intestinal bacterial enzymes, including β-glucuronidase and 7α/β-dehydroxylase, are involved in the deconjugation and dehydroxylation of primary bile acids, synthetized by the liver, into the more cytotoxic secondary bile acids. NSAID-induced changes in the microbiota can elevate secondary bile acid ratio, favoring intestinal damage (Blackler et al., 2015). Furthermore, bacterial enzymes that produce large quantities of secondary bile acids can as well amplify the damage against the intestinal mucosa by increasing the enterohepatic circulation of NSAIDs (Duggan et.al., 1975; Seitz and Boelsterli, 1998; Zhou et al., 2010). Thus, the severity of NSAID enteropathy is correlated with the amount of drug excreted in the bile and the rate of enterohepatic circulation (Duggan et al., 1975). Indeed, ligation of the bile duct prevents NSAID-induced intestinal damage in mice and in rats (Yamada et al., 1993; Jacob et al., 2007). Moreover, intestinal damage by diclofenac is prevented in rats lacking the hepatocanalicular conjugate export pump, a protein required for the excretion of conjugated NSAIDs into the bile (Seitz and Boelsterli, 1998). Finally, the use of NSAIDs that do not undergo enterohepatic recirculation is not being associated with enteropathies (Reuter et al., 1997; Somasundaram et al., 1997).
In summary, these studies provide clear evidence that the complex pathogenesis of NSAID-induced enteropathy is determined by a combination of NSAID-topical effects, COX inhibition, drug–host–microbiota interconnectedness, enterohepatic recirculation of the drug, and the effect of secondary bile acids.
Therapeutic Interventions Targeting the Gut Microbiota
The gut microbiota represents a target for therapeutic intervention since altering its functionality and metabolic capability may improve NSAID efficacy and/or to reduce NSAID side effects. Specifically several studies have reported the beneficial effects of targeting the gut microbiota against NSAID-induced small intestinal injury (Lanas and Scarpignato, 2006; Otani et al., 2017).
Some poorly absorbable antibiotics that target Gram-negative bacteria prevent NSAID-induced enteropathy in mice (Uejima et al., 1996; Koga et al., 1999; Watanabe et al., 2008a; Colucci et al., 2018) and in humans (Bjarnason et al., 1992; Davies et al., 1993; Scarpignato et al., 2017). However, these treatments are inconsistently effective in limiting intestinal damage (Syer et al., 2015). Furthermore, the use of antibiotics for extended periods of time may be deleterious since it could increase the risk of the development of multi-drug resistant bacteria and/or antibiotic-associated enteritis. Consequently, alternative agents or modes to alter the gut microbiota could represent better candidates for preventing or treating NSAID-induced enteropathy (Steidler, 2003; Mani et al., 2014; Syer et al., 2015; Gallo et al., 2016).
Supplementation with probiotics (rational selection of specific probiotic strains) in chronic users of NSAIDs may help to restore an altered intestinal microbiota (Mani et al., 2014, Table 4). Pre-treatment with viable Lactobacillus casei strain Shirota (LcS) improves indomethacin-induced enteropathy by suppressing of neutrophil infiltration and gene expression of inflammatory cytokines (Watanabe et al., 2009). Similarly, L-lactic acid produced by LcS suppresses indomethacin-induced small intestinal damage in rats (Watanabe et al., 2009). Moreover, culture supernatants of Lactobacillus acidophilus or Bifidobacterium adolescentis reduce NSAID-induced ileal damage by repressing unbalanced growth of aerobic bacteria and lipid peroxidation in rats (Kinouchi et al., 1998). Furthermore, the administration of Bifidobacterium adolescentis or Faecalibacterium prausnitzii prior naproxen treatment results in a significant reduction of the intestinal damage in rats, probably through an effect on the biosynthesis of cytoprotective short-chain fatty acids (Syer et al., 2015). Recently, it has been reported that the combination of lactoferrin with Bifidobacterium longum protects against diclofenac induced-enteropathy in rats partially by modulating the TLR-2/-4/NF-κB pathways (Fornai et al., 2020).
So far, few studies have been performed in humans to investigate whether modulation of the gut microbiota with probiotics is an effective therapeutic approach against NSAID-induced enteropathy, and the results of these studies are discordant (Montalto et al., 2013). Lactobacillus casei significantly decreases the number of intestinal mucosal lesions in patients in the low-dose aspirin group compared to those in the control group (Endo et al., 2011). Furthermore, the administration of yogurt containing Lactobacillus gasseri reduces aspirin-induced small bowel injuries and mitigates GI symptoms in a double blind study in patients (Suzuki et al., 2017). A probiotic mixture consisting of eight different live bacteria (VSL#3) significantly decreases fecal calprotectin concentration, a marker of intestinal inflammation and enteropathy, in healthy volunteers treated with indomethacin compared to those treated with placebo in a randomized double-blind, placebo controlled cross-over trial (Montalto et al., 2010). Bifidobacterium breve protects against aspirin induced small-intestinal damage in a randomized, double-blind trial of healthy volunteers (Mortensen et al., 2019). On the contrary, Lactobacillus plantarum strains did not improve the intestinal permeability altered by indomethacin in a small randomized placebo controlled cross-over study in healthy volunteers (Mujagic et al., 2017). Similarly, ingestion of live Lactobacillus GG reduces alteration of the integrity of the gastric, but not the intestinal, mucosal barrier induced by indomethacin in healthy subjects (Gotteland et al., 2001).
In addition to the use of probiotics, rebamipide, a mucosal protective agent clinically used for treating gastritis and peptic ulcers, can prevent NSAID-induced small intestinal damage and improve intestinal healing mainly by regulating the intestinal microbiota in animals (Mizoguchi et al., 2001; Diao et al., 2012; Tanigawa et al., 2013; Kurata et al., 2015; Lai et al., 2015) and in humans (Niwa et al., 2008; Fujimori et al., 2011; Mizukami et al., 2011; Kurokawa et al., 2014; Watanabe et al., 2015; Ota et al., 2016; Table 5). Several mechanisms mediate the protective effect of rebamipide against NSAID small intestinal injuries, including its ability to upregulate alpha-defensin 5 gene and protein expression in the ileal tissue, which increases the abundance of Gram-positive bacteria and reduces Gram negative microbes, as reported in mice (Tanigawa et al., 2013).
Additionally, as discussed earlier, inhibition of the hydrolytic cleavage of NSAID conjugates by targeting bacterial β-glucuronidase with small molecule reagents could represent an alternative effective intervention to improve NSAID safety profiles (Boelsterli et al., 2013).
In summary, therapeutic intervention targeting the gut microbiota is a promising approach to prevent NSAID-induced small intestinal injury, but additional data are needed from larger clinical long term longitudinal studies to assess its clinical benefits. Thus, well-designed trials taking in consideration physical activity and eating habits of the volunteers and time of administration of the probiotic should be performed to evaluate the actual role of agents targeting the microbiota to prevent NSAID enteropathy. This will also help to clarify the eventual differences among probiotic strains, dose-response relationships, and the optimal duration of therapy.
In this review, we have discussed studies that provide insight into the reciprocal NSAID–gut microbiota interactions in animal models and in humans. Such interactions are identified mostly through studies using germ-free mice and animals treated with antibiotic cocktails or colonized with specific bacterial consortia. Additional evidence for NSAID–gut microbiota interconnectedness may arise from metagenomics-based associations, microbiota environment-mimicking culture-based experiments, biochemical characterization of gut microbiota enzymes, and functional studies.
The investigation of the microbiota in animal models often fails to predict the results obtained in humans. This is due to many factors, including species-specific differences in gastrointestinal anatomy, physiology and microbiota profiles; reduced microbiota diversity and dynamics due to laboratory conditions; and genetic similarity of used rodent strains (Nguyen et al., 2015). However, the use of traditional animal models in microbiota studies allows perturbations of the intestinal microbial taxa (i.e. abiotic and gnotobiotic animals) that are necessary to help in assessing causality of the complex host-microbiota interconnectedness and in developing mechanistic hypotheses. Indeed, there are several examples of gut microbiota–drug interactions characterized in mice that have been further validated in humans, including studies with digoxin (Saha et al., 1983; Haiser et al., 2013) and proton pump inhibitors (Hung et al., 2015; Imhann et al., 2016).
Some of the studies discussed in this review are limited by the fact that they often focus on fecal metagenomics. The luminal content and different anatomical intestinal locations are characterized by significantly different microbial communities that also play a role into the host–gut microbiota metabolic interactions. Moreover, 16S ribosomal RNA sequencing profiles provide information only on the bacteria present in the gut microbiota and not on nonbacterial members of the gut community, like fungi, archaea, and viruses, which are also candidate modulators of drug metabolism and govern the dynamic microbiota composition and functionalities. Therefore, a holistic analysis that includes the archaea, the virome, the phageome, and the mycobiome may provide a more complete picture of host–microorganism-drug interconnectedness. Indeed, fungi and parasites can metabolize AA and produce immunomodulatory lipid mediators, including PGE2, PGD2 and leukotrienes, some of which modulates microbial fitness during pathogenesis (Noverr et al., 2001; Noverr et al., 2002; Hervé et al., 2003; Tsitsigiannis et al., 2005; Valdez et al., 2012; Kim et al., 2014).
The investigation of the impact of selective and nonselective NSAIDs on host/gut microbiota interactions provide new insights into the pharmacology and metabolism of NSAIDs and into the molecular mechanisms contributing to their efficacy and toxicity. Despite the important consequences of this interconnectedness for the host, the specific gut microbial strains, genes, and metabolic pathways that mediate NSAID disposition, efficacy and toxicity are still poorly understood. It still remains a challenge to link microbial biotransformation to specific enzymes and to elucidate their biological effects. Thus, further studies to improve our understanding of how host–gut microbiota and NSAIDs interact are needed to identify individual factors that influence the outcome of NSAID therapy.
DM and ER critically reviewed the literature and wrote the manuscript. DM and ER approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Annadurai, S., Guha-Thakurta, A., Sa, B., Dastidar, S. G., R Ray, R., Chakrabarty, A. N. (2002). Experimental studies on synergism between aminoglycosides and the antimicrobial antiinflammatory agent diclofenac sodium. Chemother 14, 47–53. doi: 10.1179/joc.2002.14.1.47
Bae, J. W., Choi, C. I., Jang, C. G., Lee, S. Y. (2011). Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br. J. Clin. Pharmacol. 71, 550–555. doi: 10.1111/j.1365-2125.2010.03853.x
Basivireddy, J., Jacob, M., Ramamoorthy, P., Balasubramanian, K. A. (2005). Alterations in the intestinal glycocalyx and bacterial flora in response to oral indomethacin. Int. J. Biochem. Cell Biol. 37, 2321–2332. doi: 10.1016/j.biocel.2005.05.010
Bertrand, V., Guimbaud, R., Tulliez, M., Mauprivez, C., Sogni, P., Couturier, D., et al. (1998). Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br. J. Pharmacol. 124, 1385–1394. doi: 10.1038/sj.bjp.0701968
Bjarnason, I., Smethurst, P., Fenn, C. G., Lee, C. E., Menzies, S., Levi, A. J. (1989). Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig. Dis. Sci. 34 (3), 407–411. doi: 10.1007/bf01536263
Bjarnason, I., Hayllar, J., Smethurst, P., Price, A., Gumpel, M. J. (1992). Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 33 (9), 1204–1208. doi: 10.1136/gut.33.9.1204
Bjarnason, I., Hayllar, J., MacPherson, A. J., Russell, A. S. (1993). Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104, 1832–1847. doi: 10.1016/0016-5085(93)90667-2
Bjarnason, I., Scarpignato, C., Takeuchi, K., Rainsford, K. D. (2007). Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment. Pharmacol. Ther. 26, 95–106. doi: 10.1111/j.1365-2036.2007.03348.x
Bjarnason, I., Scarpignato, C., Holmgren, E., Olszewski, M., Rainsford, K. D., Lanas, A. (2018). Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology 154, 500–514. doi: 10.1053/j.gastro.2017.10.049
Blackler, R. W., Motta, J. P., Manko, A., Workentine, M., Bercik, P., Surette, M. G., et al. (2015). Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br. J. Pharmacol. 172, 992–1004. doi: 10.1111/bph.12961
Blikslager, A. T., Zimmel, D. N., Young, K. M., Campbell, N. B., Argenzio, R. A. (2002). Recovery of ischaemic injured porcine ileum: evidence for a contributory role of COX-1 and COX-2. Gut 50 (5), 615–623. doi: 10.1136/gut.50.5.615
Boelsterli, U. A., Redinbo, M. R., Saitta, K. S. (2013). Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol. Sci. 131, 654–667. doi: 10.1093/toxsci/kfs310
Bokulich, N. A., Battaglia, T., Aleman, J. O., Walker, J. M., Blaser, M. J., Holt, P. H. (2016). Celecoxib does not alter intestinal microbiome in a longitudinal diet-controlled study. Clin. Microbiol. Infect. 22, 464–465. doi: 10.1016/j.cmi.2016.01.013
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl. J. Med. 343 (21), 1520–1528. doi: 10.1056/NEJM200011233432103
Chan, E. W. L., Yee, Z. Y., Raja, I., Yap, J. K. Y. (2017). Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin resistant Staphylococcus aureus. J. Glob. Antimicrob. Resist. 10, 70–74. doi: 10.1016/j.jgar.2017.03.012
Cheng, X., Huang, F., Zhang, K., Yuan, X., Song, C. (2018). Effects of none-steroidal anti-inflammatory and antibiotic drugs on the oral immune system and oral microbial composition in rats. Biochem. Biophys. Res. Commun. 507, 420–425. doi: 10.1016/j.bbrc.2018.11.054
Chmaisse, H. M., Antoon, J. S., Kvietys, P. R., Grisham, M. B., Perry, M. A. (1994). Role of leukocytes in indomethacin-induced small bowel injury in the rat. Am. J. Physiol. 266 (2 Pt 1), G239–G246. doi: 10.1152/ajpgi.1994.266.2.G239
Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., Nicholson, J. K. (2009). Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U. S. A. 106, 14728–14733. doi: 10.1073/pnas.0904489106
Collins, S. M., Bercik, P. (2009). The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003–2014. doi: 10.1053/j.gastro.2009.01.075
Colucci, R., Pellegrini, C., Fornai, M., Tirotta, E., Antonioli, L., Renzulli, C., et al. (2018). Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. Front. Pharmacol. 9:1340:1340. doi: 10.3389/fphar.2018.01340
Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., et al. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769–779. doi: 10.1016/S0140-6736(13)60900-9
Currò, D. (2018). The role of gut microbiota in the modulation of drug action: a focus on some clinically significant issues. Expert Rev. Clin. Pharmacol. 11, 171–183. doi: 10.1080/17512433.2018.1414598
Dalby, A. B., Frank, D. N., St Amand, A. L., Bendele, A. M., Pace, N. R. (2006). Culture-independent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota. Appl. Environ. Microbiol. 72, 6707–6715. doi: 10.1128/AEM.00378-06
Dastidar, S. G., Ganguly, K., Chaudhuri, K., Chakrabarty, A. N. (2000). The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. Int. J. Antimicrob. Agents 14 (3), 249–251. doi: 10.1016/s0924-8579(99)00159-4
Davies, G. R., Wilkie, M. E., Rampton, D. S. (1993). Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig. Dis. Sci. 38 (3), 417–425. doi: 10.1007/bf01316493
de Vos, P., Mujagic, Z., de Haan, B. J., Siezen, R. J., Bron, P. A., Meijerink, M., et al (2017). Lactobacillus plantarum Strains Can Enhance Human Mucosal and Systemic Immunity and Prevent Non-steroidal Anti-inflammatory Drug Induced Reduction in T Regulatory Cells. Front Immunol. 8, 1000. doi: 10.3389/fimmu.2017.01000
Diao, L., Mei, Q., Xu, J. M., Liu, X. C., Hu, J., Jin, J., et al. (2012). Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice. World J. Gastroenterol. 18 (10), 1059–1066. doi: 10.3748/wjg.v18.i10.1059
Duggan, D. E., Hooke, K. F., Noll, R. M., Kwan, K. C. (1975). Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem. Pharmacol. 24, 1749–1754. doi: 10.1016/0006-2952(75)90450-5
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., et al. (2005). Diversity of the human intestinal microbial flora. Science 308, 1635–1638. doi: 10.1126/science.1110591
Edogawa, S., Peters, S. A., Jenkins, G. D., Gurunathan, S. V., Sundt, W. S., Johnson, S., et al. (2018). Sex differences in NSAID-induced perturbationof human intestinal barrier function and microbiota. FASEB J. 32 (12), fj201800560R. doi: 10.1096/fj.201800560R
Endo, H., Higurashi, T., Hosono, K., Sakai, E., Sekino, Y., Iida, H., et al. (2011). Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J. Gastroenterol. 46 (7), 894–905. doi: 10.1007/s00535-011-0410-1
Endo, H., Sakai, E., Taniguchi, L., Kessoku, T., Komiya, A., Ezuka, A., et al. (2014). Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest. Endosc. 80, 826–834. doi: 10.1016/j.gie.2014.03.024
Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., et al. (2016). Population-level analysis of gut microbiome variation. Science 352 (6285), 560–564. doi: 10.1126/science.aad3503
Fornai, M., Antonioli, L., Colucci, R., Pellegrini, C., Giustarini, G., Testai, L., et al. (2014). NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? J. Pharmacol. Exp. Ther. 348, 86–95. doi: 10.1124/jpet.113.207118
Fornai, M., Antonioli, L., Pellegrini, C., Colucci, R., Sacco, D., Tirotta, E., et al. (2016). Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacol. Res. 104, 186–196. doi: 10.1016/j.phrs.2015.12.031
Fornai, M., Pellegrini, C., Benvenuti, L., Tirotta, E., Gentile, G., Natale, G., et al. (2020). Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy. Nutrition 70:110583. doi: 10.1016/j.nut.2019.110583
Fries, S., Grosser, T., Price, T. S., Lawson, J. A., Kapoor, S., DeMarco, S., et al. (2006). Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130 (1), 55–64. doi: 10.1053/j.gastro.2005.10.002
Fujimori, S., Seo, T., Gudis, K., Ehara, A., Kobayashi, T., Mitsui, K., et al. (2009). Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest. Endosc. 69 (7), 1339–1346. doi: 10.1016/j.gie.2008.08.017
Fujimori, S., Takahashi, Y., Gudis, K., Seo, T., Ehara, A., Kobayashi, T., et al. (2011). Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 46 (1), 57–64. doi: 10.1007/s00535-010-0332-3
Furuhashi, H., Higashiyama, M., Okada, Y., Kurihara, C., Wada, A., Horiuchi, K., et al. (2019). Dietary emulsifier polysorbate-80-induced small-intestinal vulnerability to indomethacin-induced lesions via dysbiosis. J. Gastroenterol. Hepatol. 35 (1), 110–117. doi: 10.1111/jgh.14808
Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H., et al. (1993). NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 24 (1), 105–110. doi: 10.1016/0306-3623(93)90018-s
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., Montalto, M. (2016). Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J. Gastroenterol. 22, 7186–7202. doi: 10.3748/wjg.v22.i32.7186
Geis, G. S., Stead, H., Wallemark, C. B., Nicholson, P. A. (1991). Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J. Rheumatol. Suppl. 28, 11–14.
Gotteland, M., Cruchet, S., Verbeke, S. (2001). Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment. Pharmacol. Ther. 15 (1), 11–17. doi: 10.1046/j.1365-2036.2001.00898.x
Gretzer, B., Maricic, N., Respondek, M., Schuligoi, R., Peskar, B. M. (2001). Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br. J. Pharmacol. 132, 1565–1573. doi: 10.1038/sj.bjp.0703955
Hagiwara, M., Kataoka, K., Arimochi, H., Kuwahara, T., Ohnishi, Y. (2004). Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J. Med. Invest. 51, 43–51. doi: 10.2152/jmi.51.43
Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., Turnbaugh, P. J. (2013). Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295–298. doi: 10.1126/science.1235872
Handa, O., Naito, Y., Fukui, A., Omatsu, T., Yoshikawa, T. (2014). The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium. J. Clin. Biochem. Nutr. 54 (1), 2–6. doi: 10.3164/jcbn.13-84
Hatazawa, R., Ohno, R., Tanigami, M., Tanaka, A., Takeuchi, K. (2006). Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats. J. Pharmacol. Exp. Ther. 318 (2), 691–699. doi: 10.1124/jpet.106.103994
Hawkey, C., Laine, L., Simon, T., Beaulieu, A., Maldonado-Cocco, J., Acevedo, E., et al. (2000). Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheumatol. 43 (2), 370–377. doi: 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D
Haworth, R., Oakley, K., McCormack, N., Pilling, A. (2005). Differential expression of COX-1 and COX-2 in the gastrointestinal tract of the rat. Toxicol. Pathol. 33, 239–245. doi: 10.1080/01926230590906512
Hernandez-Sanabria, E., Heiremans, E., Calatayud Arroyo, M., Props, R., Leclercq, L., Snoeys, J., et al. (2020). Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation. NPJ Biofilms Microbiomes 6 (1), 9. doi: 10.1038/s41522-020-0119-0
Hervé, M., Angeli, V., Pinzar, E., Wintjens, R., Faveeuw, C., Narumiya, S., et al. (2003). Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion. Eur. J. Immunol. 33, 2764–2772. doi: 10.1002/eji.200324143
Higashimori, A., Watanabe, T., Nadatani, Y., Takeda, S., Otani, K., Tanigawa, T., et al. (2016). Mechanisms of NLRP3 inflammasome activation and its role in NSAID-induced enteropathy. Mucosal. Immunol. 9 (3), 659–668. doi: 10.1038/mi.2015.89
Hiyama, S., Iijima, H., Shinzaki, S., Inoue, T., Shiraishi, E., Kawai, S., et al. (2014). Peyer’s patches play a protective role in nonsteroidal anti-inflammatory drug-induced enteropathy in mice. Inflammation Bowel. Dis. 20 (5), 790–799. doi: 10.1097/MIB.0000000000000017
Honda, K., Matsumoto, T., Kuroki, F., Iida, M., Oka, M., Sawatani, I. (1999). Protective effect of lactosucrose on intracolonic indomethacin-induced small-intestinal ulcers in rats. Scand. J. Gastroenterol. 34, 264–269. doi: 10.1080/00365529950173663
Hotz-Behofsits, C., Simpson, R. J., Walley, M., Bjarnason, I. T. (2010). Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents. Scand. J. Gastroenterol. 45 (7-8), 822–827. doi: 10.3109/00365521003797205
Hung, Y. P., Ko, W. C., Chou, P. H., Chen, Y. H., Lin, H.-J., Liu, Y.-H., et al. (2015). Proton-Pump Inhibitor Exposure Aggravates Clostridium difficile-Associated Colitis: Evidence From a Mouse Model. J. Infect. Dis. 212, 654–663. doi: 10.1093/infdis/jiv184
Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., et al. (2012). Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214. doi: 10.1038/nature11234
Jacob, M., Foster, R., Sigthorsson, G., Simpson, R., Bjarnason, I. (2007). Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch. Toxicol. 81 (4), 291–298. doi: 10.1007/s00204-006-0149-2
Karaźniewicz-Łada, M., Luczak, M., Główka, F. (2009). Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica 39, 476–485. doi: 10.1080/00498250902862705
Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., et al. (1996). Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111, 445–454. doi: 10.1053/gast.1996.v111.pm8690211
Kim, Y. G., Udayanga, K. G., Totsuka, N., Weinberg, J. B., Núñez, G., Shibuya, A. (2014). Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂. Cell Host. Microbe 15, 95–102. doi: 10.1016/j.chom.2013.12.010
Kim, I. S., Yoo, D. H., Jung, I. H., Lim, S., Jeong, J.-J., Kim, K.-A., et al. (2016). Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin. Biochem. Pharmacol. 122, 72–79. doi: 10.1016/j.bcp.2016.09.023
Kinouchi, T., Kataoka, K., Bing, S. R., Nakayama, H. (1998). Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Microbiol. Immunol. 42, 347–355. doi: 10.1111/j.1348-0421.1998.tb02294.x
Kirkby, N. S., Chan, M. V., Zaiss, A. K., Garcia-Vaz, E., Jiao, J., Berglund, L. M., et al. (2016). Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-κB and NFAT transcriptional pathways. Proc. Natl. Acad. Sci. U. S. A. 113 (2), 434–439. doi: 10.1073/pnas.1517642113
Koga, H., Aoyagi, K., Matsumoto, T., Iida, M., Fujishima, M. (1999). Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. Am. J. Physiol. 276 (3), G576–G582. doi: 10.1152/ajpgi.1999.276.3.G576
Konaka, A., Kato, S., Tanaka, A., Kunikata, T., Korolkiewicz, R., Takeuchi, K. (1999). Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol. Res. 40 (6), 517–524. doi: 10.1006/phrs.1999.0550
Kunikata, T., Araki, H., Takeeda, M., Kato, S., Takeuchi, K. (2001). Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes. J. Physiol. Paris 95 (1-6), 157–163. doi: 10.1016/s0928-4257(01)00021-3
Kunikata, T., Tanaka, A., Miyazawa, T., Kato, S., Takeuchi, K. (2002). 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig. Dis. Sci. 47 (4), 894–904. doi: 10.1023/a:1014725024519
Kurata, S., Nakashima, T., Osaki, T., Uematsu, N., Shibamori, M., Sakurai, K., et al. (2015). Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J. Clin. Biochem. Nutr. 56 (1), 20–27. doi: 10.3164/jcbn.14-67
Kurokawa, S., Katsuki, S., Fujita, T., Saitoh, Y., Ohta, H., Nishikawa, K., et al. (2014). A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J. Gastroenterol. 49 (2), 239–244. doi: 10.1007/s00535-013-0805-2
Kyaw, M. H., Otani, K., Ching, J. Y. L., Higashimori, A., Kee, K. M., Watanabe, T., et al. (2018). Misoprostol heals small bowel ulcers in aspirin users with small bowel bleeding. Gastroenterology 155, 1090–1097. doi: 10.1053/j.gastro.2018.06.056
Lai, Y., Zhong, W., Yu, T., Xia, Z. S. 1., Li, J.-Y., Ouyang, H., et al. (2015). Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin. PloS One 10 (7), e0132031. doi: 10.1371/journal.pone.0132031
Lanas, A., García-Rodríguez, L. A., Polo-Tomás, M., Ponce, M., Quintero, E., Perez-Aisa, M. A., et al. (2011). The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment. Pharmacol. Ther. 33, 585–591. doi: 10.1111/j.1365-2036.2010.04563.x
Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, P. C., et al. (1995). Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83, 483–492. doi: 10.1016/0092-8674(95)90126-4
Langenbach, R., Loftin, C., Lee, C., Tiano, H. (1999). Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem. Pharmacol. 58, 1237–1246. doi: 10.1016/s0006-2952(99)00158-6
Lanza, F. L., Rack, M. F., Simon, T. J., Quan, H. (1999). Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment. Pharmacol. Ther. 13 (6), 761–767. doi: 10.1046/j.1365-2036.1999.00529.x
Lázár, B., Brenner, G. B., Makkos, A., Balogh, M., László, S. B., Al-Khrasani, M., et al. (2019). Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat. Cells 8 (3), pii: E251. doi: 10.3390/cells8030251
Lee, S. J., Park, M. K., Shin, D. S., Chun, M. H. (2017). Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism. Drug Des. Devel. Ther. 11, 2727–2736. doi: 10.2147/DDDT.S143807
Leite, A. Z., Sipahi, A. M., Damião, A. O., Coelho, A. M., Garcez, A. T., Machad, M. C., et al. (2001). Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism. Gut 48, 163–167. doi: 10.1136/gut.48.2.163
Liang, X., Bittinger, K., Li, X., Abernethy, D. R., Bushman, F. D., FitzGerald, G. A. (2015). Bidirectional interactions between indomethacin and the murine intestinal microbiota. Elife 4, e08973. doi: 10.7554/eLife.08973
Little, M. S., Pellock, S. J., Walton, W. G., Tripathy, A., Redinbo, M. R. (2018). Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae. Proc. Natl. Acad. Sci. U. S. A. 115 (2), E152–E161. doi: 10.1073/pnas.1716241115
Loftin, C. D., Tiano, H. F., Langenbach, R. (2002). Phenotypes of the COX-deficient mice indicatephysiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 68–69, 177–185. doi: 10.1016/s0090-6980(02)00028-x
LoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R., Boelsterli, U. A. (2012). Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. Pharmacol. Exp. Ther. 341, 447–454. doi: 10.1124/jpet.111.191122
Lué, A., Lanas, A. (2016). Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits. World J. Gastroenterol. 22 (48), 10477–10481. doi: 10.3748/wjg.v22.i48.10477
Maehata, Y., Esaki, M., Morishita, T., Kochi, S., Endo, S., Shikata, K., et al. (2012). Small bowel injury induced by selective cyclooxygenase-2 inhibitors: A prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam. J. Gastroenterol. 47, 387–393. doi: 10.1007/s00535-011-0501-z
Maiden, L., Thjodleifsson, B., Theodors, A., Gonzalez, J., Bjarnason, I. (2005). A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128, 1172–1178. doi: 10.1053/j.gastro.2005.03.020
Maiden, L., Thjodleifsson, B., Seigal, A., Bjarnason, I. I., Scott, D., Birgisson, S., et al. (2007). Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: A cross-sectional capsule enteroscopy study. Clin. Gastroenterol. Hepatol. 5, 1040–1045. doi: 10.1016/j.cgh.2007.04.031
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., et al. (2018). Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628. doi: 10.1038/nature25979
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., Balskus, E. P. (2019). Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, 6445. doi: 10.1126/science.aau6323
Mäkivuokko, H., Tiihonen, K., Tynkkynen, S., Paulin, L., Rautonen, N. (2010). The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. Br. J. Nutr. 103, 227–234. doi: 10.1017/S0007114509991553
Malmi, H., Kautiainen, H., Virta, L. J., Färkkilä, N., Koskenpato, J., Färkkilä, M. A. (2014). Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment. Pharmacol. Ther. 39, 496–506. doi: 10.1111/apt.12620
Mani, S., Boelsterli, U. A., Redinbo, M. R. (2014). Understanding and modulating mammalian-microbial communication for improved human health. Annu. Rev. Pharmacol. Toxicol. 54, 559–580. doi: 10.1146/annurev-pharmtox-011613-140007
Maseda, D., Zackular, J. P., Trindade, B., Kirk, L., Lising Roxas, J., Rogers, L. M., et al. (2019). Nonsteroidal Anti-inflammatory Drugs Alter theMicrobiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response. MBio 10 (1), e02282–18. doi: 10.1128/mBio.02282-18
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., et al. (1994). Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U. S. A. 91, 3228–3232. doi: 10.1073/pnas.91.8.3228
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., FitzGerald, G. A. (1999). Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A. 96, 272–277. doi: 10.1073/pnas.96.1.272
Melarange, R., Moore, G., Blower, P. R., Coates, M. E., Ward, F. W., Ronaasen, V. (1992). A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ-free rats. Aliment. Pharmacol. Ther. 6 (1), 67–77. doi: 10.1111/j.1365-2036.1992.tb00546.x
Mizoguchi, H., Ogawa, Y., Kanatsu, K., Tanaka, A., Kato, S., Takeuchi, K. (2001). Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J. Gastroenterol. Hepatol. 16 (10), 1112–1119. doi: 10.1046/j.1440-1746.2001.02592.x
Mizukami, K., Murakami, K., Abe, T., Inoue, K., Uchida, M., Okimoto, T., et al. (2011). Aspirin induced small bowel injuries and the preventive effect of rebamipide. World J. Gastroenterol. 17, 5117–5122. doi: 10.3748/wjg.v17.i46.5117
Montalto, M., Gallo, A., Curigliano, V., D’Onofrio, F., Santoro, L., Covino, M., et al. (2010). Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study. Aliment. Pharmacol. Ther. 32 (2), 209–214. doi: 10.1111/j.1365-2036.2010.04324.x
Montrose, D. C., Zhou, X. K., McNally, E. M., Sue, E., Yantiss, R. K., Gross, S. S., et al. (2016). Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden. Cancer Prev. Res. (Phila.) 9, 721–731. doi: 10.1158/1940-6207.CAPR-16-0095
Morham, S. G., Langenbach, R., Loftin, C. D., Tiano, H. F., Vouloumanos, N., Jennette, J. C., et al. (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83, 473–482. doi: 10.1016/0092-8674(95)90125-6
Morhardt, T. L., Hayashi, A., Ochi, T., Quirós, M., Kitamoto, S., Nagao-Kitamoto, H., et al. (2019). IL-10 produced by macrophages regulates epithelial integrity in the small intestine. Sci. Rep. 9 (1), 1223. doi: 10.1038/s41598-018-38125-x
Mortensen, B., Murphy, C., O’Grady, J., Lucey, M., Elsafi, G., Barry, L., et al. (2019). Bifidobacteriumbreve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers. Gastroenterology 157 (3), 637–646.e4. doi: 10.1053/j.gastro.2019.05.008
Mujagic, Z., de Vos, P., Boekschoten, M. V., Govers, C., Pieters, H.-J. H. M., de Wit, N. J. W., et al. (2017). The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription: a randomized double-blind placebo controlled trial. Sci. Rep. 7:40128. doi: 10.1038/srep40128
Muñoz-Miralles, J., Trindade, B. C., Castro-Córdova, P., Bergin, I. L., Kirk, L. A., Fernando Gil, F., et al. (2018). Indomethacin increases severity of Clostridium difficile infection in mouse model. Future Microbiol. 13, 1271–1281. doi: 10.2217/fmb-2017-0311
Nadatani, Y., Watanabe, T., Tanigawa, T., Machida, H., Okazaki, H., Yamagami, H., et al. (2012). High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. Am. J. Pathol. 181 (1), 98–110. doi: 10.1016/j.ajpath.2012.03.039
Nadatani, Y., Watanabe, T., Suda, W., Nakata, A., Matsumoto, Y., Kosaka, S., et al. (2019). Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii. Sci. Rep. 9 (1), 17490. doi: 10.1038/s41598-019-53559-7
Niwa, Y., Nakamura, M., Ohmiya, N., Maeda, O., Maeda, O., Ando, T., et al. (2008). Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J. Gastroenterol. 43 (4), 270–276. doi: 10.1007/s00535-007-2155-4
Noverr, M. C., Phare, S. M., Toews, G. B., Coffey, M. J., Huffnagle, G. B. (2001). Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69, 2957–2963. doi: 10.1128/IAI.69.5.2957-2963.2001
Ohno, R., Yokota, A., Tanaka, A., Takeuchi, K. (2004). Induction of small intestinal damage in rats following combined treatment with cyclooxygenase-2 and nitric-oxide synthase inhibitors. J. Pharmacol. Exp. Ther. 310 (2), 821–827. doi: 10.1124/jpet.104.065961
Ota, K., Takeuchi, T., Nouda, S., Ozaki, H., Kawaguchi, S., Yoshiaki Takahashi, Y., et al. (2016). Determination of the adequate dosage of rebamipide, a gastric mucoprotective drug, to prevent low-dose aspirin-induced gastrointestinal mucosal injury. J. Clin. Biochem. Nutr. 59, 231–237. doi: 10.3164/jcbn.16-49
Otani, K., Tanigawa, T., Watanabe, T., Shimada, S., Kawaguchi, S., Takahashi, Y., et al. (2017). Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion 95 (1), 22–28. doi: 10.1159/000452356
Panara, M. R., Renda, G., Sciulli, M. G., Santini, G., Di Giamberardino, M., Rotondo, M. T., et al. (1999). Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J. Pharmacol. Exp. Ther. 290, 276–280.
Permpalung, N., Upala, S., Sanguankeo, A., Sornprom, S. (2016). Association between NSAIDs and Clostridium difficile-Associated Diarrhea: A Systematic Review and Meta-Analysis. Can. J. Gastroenterol. Hepatol. 2016, 7431838. doi: 10.1155/2016/7431838
Pollet, R. M., D’Agostino, E. H., Walton, W. G., Xu, Y., Little, M. S., Biernat, K. A., et al. (2017). An Atlas of β-Glucuronidases in the Human Intestinal Microbiome. Structure 225 (7), 967–977.e5. doi: 10.1016/j.str.2017.05.003
Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65. doi: 10.1038/nature08821
Reuter, B. K., Davies, N. M., Wallace, J. L. (1997). Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112, 109–117. doi: 10.1016/s0016-5085(97)70225-7
Saitta, K. S., Zhang, C., Lee, K. K., Fujimoto, K., Redinbo, M. R., Boelsterli, U. A. (2014). Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 44, 28–35. doi: 10.3109/00498254.2013.811314
Scarpignato, C., Dolak, W., Lanas, A., Matzneller, P., Renzulli, C., Grimaldi, M., et al. (2017). Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. Gastroenterology 152 (5), 980–982.e3. doi: 10.1053/j.gastro.2016.12.007
Seitz, S., Boelsterli, U. A. (1998). Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115 (6), 1476–1482. doi: 10.1016/s0016-5085(98)70026-5
Shirin, H., Moss, S. F., Kancherla, S., Kancherla, K., Holt, P. R., Weinstein, I. B., et al. (2006). Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori. J. Gastroenterol. Hepatol. 21, 1388–1393. doi: 10.1111/j.1440-1746.2006.04194.x
Sigthorsson, G., Tibble, J., Hayllar, J., Menzies, I., Macpherson, A., Moots, R., et al. (1998). Intestinal permeability and inflammation in patients on NSAIDs. Gut 43, 506–511. doi: 10.1136/gut.43.4.506
Sigthorsson, G., Simpson, R. J., Walley, M., Anthony, A., Foster, R., Hotz-Behoftsitz, C., et al. (2002). COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122, 1913–1923. doi: 10.1053/gast.2002.33647
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., et al. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (10), 1247–1255. doi: 10.1001/jama.284.10.1247
Simon, L. S., Weaver, A. L., Graham, D. Y., Kivitz, A. J., Lipsky, P. E., Hubbard, R. C., et al. (1999). Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282 (20), 1921–1928. doi: 10.1001/jama.282.20.1921
Somasundaram, S., Rafi, S., Hayllar, J., Sigthorsson, G., Jacob, M., Price, A. B., et al. (1997). Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut 41, 344–353. doi: 10.1136/gut.41.3.344
Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., Basit, A. W. (2008). The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363, 1–25. doi: 10.1016/j.ijpharm.2008.07.009
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., Turnbaugh, P. J. (2016). The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273–287. doi: 10.1038/nrmicro.2016.17
Strong, H. A., Renwick, A. G., George, C. F., Liu, Y. F., Hill, M. J. (1987). The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica 17, 685–696. doi: 10.3109/00498258709043976
Sugimura, N., Otani, K., Watanabe, T., Nakatsu, G., Shimada, S., Fujimoto, K., et al. (2019). High-fat diet-mediated dysbiosis exacerbates NSAID-induced small intestinal damage through the induction of interleukin-17A. Sci. Rep. 9, 16796. doi: 10.1038/s41598-019-52980-2
Sumida, H., Lu, E., Chen, H., Yang, Q., Mackie, K., Cyster, J. G. (2017). GPR55 regulates intraepithelial lymphocyte migration dynamics and susceptibility to intestinal damage. Sci. Immunol. 2 (18), pii: eaao1135. doi: 10.1126/sciimmunol.aao1135
Suzuki, T., Masui, A., Nakamura, J., Shiozawa, H., Aoki, J., Nakae, H., et al. (2017). Yogurt Containing Lactobacillus gasseri Mitigates Aspirin-Induced Small Bowel Injuries: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Digestion 95 (1), 49–54. doi: 10.1159/000452361
Syer, S. D., Blackler, R. W., Martin, R., de Palma, G., Rossi, L., Verdu, E., et al. (2015). NSAID enteropathy and bacteria: a complicated relationship. J. Gastroenterol. 50 (4), 387–393. doi: 10.1007/s00535-014-1032-1
Taha, A. S., McCloskey, C., McSkimming, P., McConnachie, A. (2018). Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol. Hepatol. 3, 469–476. doi: 10.1016/S2468-1253(18)30119-5
Takeuchi, K., Amagase, K. (2018). Roles of Cyclooxygenase, Prostaglandin E2 and EP Receptors in Mucosal Protection and Ulcer Healing in the Gastrointestinal Tract. Curr. Pharm. 24 (18), 2002–2011. doi: 10.2174/1381612824666180629111227
Takeuchi, K., Tanaka, A., Kato, S., Amagase, K., Satoh, H. (2010a). Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin. Chim. Acta 411, 459–466. doi: 10.1016/j.cca.2009.12.026
Takeuchi, K., Tanigami, M., Amagase, K., Ochi, A., Okuda, S., Hatazawa, R. (2010b). Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors. J. Gastroenterol. Hepatol. 25 Suppl;1, S67–S74. doi: 10.1111/j.1440-1746.2010.06222.x
Takeuchi, K. (2014). Prophylactic effects of prostaglandin E2 on NSAID-induced enteropathy-role of EP4 receptors in its protective and healing-promoting effects. Curr. Opin. Pharmacol. 19, 38–45. doi: 10.1016/j.coph.2014.07.005
Tanaka, A., Araki, H., Komoike, Y., Hase, S., Takeuchi, K. (2001). Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris 95 (1-6), 21–27. doi: 10.1016/s0928-4257(01)00005-5
Tanaka, A., Hase, S., Miyazawa, T., Takeuchi, K. (2002a). Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J. Pharmacol. Exp. Ther. 300 (3), 754–761. doi: 10.1124/jpet.300.3.754
Tanaka, A., Hase, S., Miyazawa, T., Ohno, R., Takeuchi, K. (2002b). Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J. Pharmacol. Exp. Ther. 303 (3), 1248–1254. doi: 10.1124/jpet.102.041715
Tanigawa, T., Watanabe, T., Otani, K., Nadatani, Y., Ohkawa, F., Sogawa, M., et al. (2013). Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of α-defensin 5. Eur. J. Pharmacol. 704 (1-3), 64–69. doi: 10.1016/j.ejphar.2013.02.010
Terán-Ventura, E., Aguilera, M., Vergara, P., Martínez, V. (2014). Specific changes of gut commensal microbiota and TLRs during indomethacin-induced acute intestinal inflammation in rats. J. Crohns. Colitis 8, 1043–1054. doi: 10.1016/j.crohns.2014.02.001
Theken, K. N., Hersh, E. V., Lahens, N. F., Lee, H. M., Li, X., Granquist, E. J., et al. (2019). Variability in the Analgesic Response to Ibuprofen Is Associated With Cyclooxygenase Activation in Inflammatory Pain. Clin. Pharmacol. Ther. 106, 632–641. doi: 10.1002/cpt.1446
Thomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., et al. (2017). The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Res. 77, 1783–1812. doi: 10.1158/0008-5472.CAN-16-2929
Ticinesi, A., Milani, C., Lauretani, F., Nouvenne, A., Mancabelli, L., Lugli, G. A., et al. (2017). Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci. Rep. 7, 11102. doi: 10.1038/s41598-017-10734-y
Treinen-Moslen, M., Kanz, M. F. (2006). Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road. Pharmacol. Ther. 112 (3), 649–667. doi: 10.1016/j.pharmthera.2006.05.007
Tsitsigiannis, D. I., Bok, J. W., Andes, D., Nielsen, K. F., Frisvad, J. C., Keller, N. P. (2005). Aspergillus cyclooxygenase-like enzymes are associated with prostaglandin production and virulence. Infect. Immun. 73, 4548–4559. doi: 10.1128/IAI.73.8.4548-4559.2005
Uejima, M., Kinouchi, T., Kataoka, K., Hiraoka, I. (1996). Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol. Immunol. 40 (8), 553–560. doi: 10.1111/j.1348-0421.1996.tb01108.x
Valdez, P. A., Vithayathil, P. J., Janelsins, B. M., Shaffer, A. L., Williamson, P. R., Datta, S. K. (2012). Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells. Immunity 36, 668–679. doi: 10.1016/j.immuni.2012.02.013
Vayssier-Taussat, M., Albina, E., Citti, C., Cosson, J. F., Jacques, M.-A., Lebrun, M.-H., et al. (2014). Shifting the paradigm from pathogens to pathobiome: new concepts in the light of meta-omics. Front. Cell Infect. Microbiol. 4, 29. doi: 10.3389/fcimb.2014.00029
Vázquez-Baeza, Y., Callewaert, C., Debelius, J., Hyde, E., Marotz, C., Morton, J. T., et al. (2018). Impacts of the Human Gut Microbiome on Therapeutics. Annu. Rev. Pharmacol. Toxicol. 58, 253–270. doi: 10.1146/annurev-pharmtox-042017-031849
Wallace, J. L., McKnight, W., Reuter, B. K., Vergnolle, N. (2000). NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119, 706–714. doi: 10.1053/gast.2000.16510
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., et al. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835. doi: 10.1126/science.1191175
Wallace, J. L., Caliendo, G., Santagada, V., Cirillo, G. (2010). Markedly Reduced Toxicity of a Hydrogen Sulphide-Releasing Derivative of Naproxen (ATB-346). Br. J. Pharmacol. 159 (6), 1236–1246. doi: 10.1111/j.1476-5381.2009.00611
Wallace, J. L., Syer, S., Denou, E., de Palma, G., Vong, L., McKnight, W., et al. (2011). Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141 (4), 1314–22, 1322.e1-5. doi: 10.1053/j.gastro.2011.06.075
Washio, E., Esaki, M., Maehata, Y., Miyazaki, M., Kobayashi, H., Ishikawa, H., et al. (2016). Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 14 (6), 809–15.e1. doi: 10.1016/j.cgh.2015.10.022
Watanabe, T., Higuchi, K., Kobata, A., Nishio, H., Tanigawa, T., Shiba, M., et al. (2008a). Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57, 181–187. doi: 10.1136/gut.2007.125963
Watanabe, T., Sugimori, S., Kameda, N., Machida, H., Okazaki, H., Tanigawa, T., et al. (2008b). Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin. Gastroenterol. Hepatol. 6 (11), 1279–1282. doi: 10.1016/j.cgh.2008.06.021
Watanabe, T., Nishio, H., Tanigawa, T., Yamagami, H., Okazaki, H., Watanabe, K., et al. (2009). Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am. J. Physiol. Gastrointest. Liver Physiol. 297 (3), G506–G513. doi: 10.1152/ajpgi.90553.2008
Watanabe, T., Tanigawa, T., Nadatani, Y., Nagami, Y. (2013). Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig. Liver Dis. 45 (5), 390–395. doi: 10.1016/j.dld.2012.12.005
Watanabe, T., Takeuchi, T., Handa, O., Sakata, Y., Tanigawa, T., Shiba, M., et al. (2015). A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PloS One 10 (4), e0122330. doi: 10.1371/journal.pone.0122330
Whitfield-Cargile, C. M., Cohen, N. D., Chapkin, R. S., Weeks, B. R., Davidson, L. A., Goldsby, J. S., et al. (2016). The microbiota-derived metabolite indole decreases mucosal inflammation and injury in a murine model of NSAID enteropathy. Gut Microbes 7 (3), 246–261. doi: 10.1080/19490976.2016.1156827
Wilkinson, E. M., Ilhan, Z. E., Herbst-Kralovetz, M. M. (2018). Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics. Maturitas 112, 53–63. doi: 10.1016/j.maturitas.2018.03.012
Yamada, T., Deitch, E., Specian, R. D., Perry, M. A., Sartor, R. B., Grisham, M. B. (1993). Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17, 641–662. doi: 10.1007/bf00920471
Yoshikawa, K., Kurihara, C., Furuhashi, H., Takajo, T., Maruta, K., Yasutake, Y., et al. (2017). Psychological stress exacerbates NSAID-induced small bowel injury by inducing changes in intestinal microbiota and permeability via glucocorticoid receptor signaling. J. Gastroenterol. 52 (1), 61–71. doi: 10.1007/s00535-016-1205-1
Yu, Y., Ricciotti, E., Scalia, R., Tang, S. Y., Grant, G., Yu, Z., et al. (2012). Vascular COX-2 Modulates Blood Pressure and Thrombosis in Mice. Sci. Transl. Med. 4 (132), 132ra54. doi: 10.1126/scitranslmed.3003787
Zhernakova, A., Kurilshikov, A., Bonder, M. J., Tigchelaar, E. F., Schirmer, M., Vatanen, T., et al. (2016). Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352 (6285), 565–569. doi: 10.1126/science.aad3369
Zhong, Z. Y., Sun, B. B., Shu, N., Xie, Q. S., Tang, X.-G., Ling, Z.-L., et al. (2016). Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity. Acta Pharmacol. Sin. 37, 1002–1012. doi: 10.1038/aps.2016.54
Zhou, Y., Dial, E. J., Doyen, R., Lichtenberger, L. M. (2010). Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am. J. Physiol. Gastrointest. Liver Physiol. 298 (5), G722–G731. doi: 10.1152/ajpgi.00387.2009
Zwolinska-Wcislo, M., Krzysiek-Maczka, G., Ptak-Belowska, A., Karczewska, E., Pajdo, R., Sliwowski, Z., et al. (2011). Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. J. Physiol. Pharmacol. 62 (3), 357–368.
Keywords: NSAIDS (nonsteroidal anti-inflammatory drugs), microbiota (microorganisms), dysbiosis, enteropathy, prostanoid, cyclooxygenase
Citation: Maseda D and Ricciotti E (2020) NSAID–Gut Microbiota Interactions. Front. Pharmacol. 11:1153. doi: 10.3389/fphar.2020.01153
Received: 04 May 2020; Accepted: 15 July 2020;
Published: 07 August 2020.
Edited by:Thorsten Jürgen Maier, Paul-Ehrlich-Institut (PEI), Germany
Reviewed by:Angel Lanas, University of Zaragoza, Spain
Marina Korotkova, Karolinska Institutet (KI), Sweden
Copyright © 2020 Maseda and Ricciotti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Emanuela Ricciotti, email@example.com